Amgen on Dec. 12 said it reached an agreement to acquire Horizon Therapeutics in a $27.8 billion deal, winning a bidding war that included Johnson & Johnson and Sanofi. Horizon focuses on anti-inflammatory and autoimmune drugs — its lead products include the eye drug Tepezza, anti-grout drug Krystexxa and immunosuppressant Uplinza. The drugmaker brought in $3.2 billion in global sales for 2021. Its most recent FDA approval was a July 2022 label expansion for Krystexxa in uncontrolled gout. For the treatment of gouty arthritis, Krystexxa currently holds covered or better status for 56% of all insured lives under the pharmacy benefit, and 82% under the medical benefit.